Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of both complex mixture generic and novel drugs.
Spotlight
Momenta Pharmaceuticals Provides Litigation Update
-District Court denies sanofi-aventis request for preliminary injunction for generic Lovenox®-
CAMBRIDGE, MA — August 26, 2010 — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC’s request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the Company’s collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generic version of Lovenox®. The decision is subject to appeal.
Momenta Pharmaceuticals Announces FDA Approval for
First Generic Lovenox®
CAMBRIDGE, MA — July 23, 2010 — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application (ANDA) for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration agreement between Momenta and Sandoz, this product has been designated therapeutically equivalent to the reference-listed drug, Lovenox®, which is marketed by Sanofi-Aventis.
“The approval of M-Enoxaparin marks a key milestone for Momenta, and we are extremely pleased,” commented Craig Wheeler, President and CEO. “This is the first product based on Momenta’s technology platform to be approved, and demonstrates our ability to characterize and develop a complex mixture drug like Lovenox.”
Results of the M118 EMINENCE trial were published in the journal Circulation. Click here to download
Momenta Pharmaceuticals Reports Financial Results for the First Quarter of 2010
CAMBRIDGE, MA — May 6, 2010 — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended March 31, 2010.
